# Integra LifeSciences Holdings Corporation (IART) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Health Care Technology. Price $16.72, market value $1.3 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Integra LifeSciences Holdings Corporation reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 0.8×**. Each dollar of revenue is priced at 0.8×, a low multiple typical of thin-margin businesses or out-of-favour stocks.
- **Price / book: 1.2×**. The shares trade at 1.2× book value; book value is a meaningful part of the valuation.
- **Free-cash-flow yield: 2.0%** (5-yr avg 1.9%). Free cash flow equals 2.0% of the market value, in line with its five-year average of 1.9%.

## Profitability
- **Operating margin: 4.0%**. 4.0% of revenue is left after running the business, which leaves little cushion in a downturn.
- **Net margin: -31.6%**. The company reported a net loss over the last twelve months.
- **Return on equity: -49.5%**. Return on equity is negative because earnings are negative.
- **Return on invested capital: 3.4%**. Return on all capital, debt included, is 3.4%: close to or below the cost of capital, so growth may not create value.
- **Return on assets: -0.2%**. Each dollar of assets produces -0.2% of profit.

## Growth
- **Revenue growth (1 yr): 1.5%** (3-yr 1.6%/yr, 5-yr 3.6%/yr). Revenue grew 1.5% over the last year, against 3.6% a year compounded over five years: growth is slowing.

## Financial health
- **Debt to equity: 0.70**. Debt is 0.70 times equity, moderate leverage.
- **Altman Z-score: 0.71**. A Z-score of 0.71 is in the distress zone, a signal to examine the balance sheet closely.
- **Piotroski F-score: 4/9**. 4 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. Integra LifeSciences Holdings Corporation does not currently pay a dividend.

## Analyst view
- **Analyst consensus: hold** (9 analysts). 9 analysts cover Integra LifeSciences Holdings Corporation; the consensus is hold, with an average price target of $19.56 (+17% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 6.8%** (YTD 34.6%, 3-mo -1.6%). The shares are up 6.8% over twelve months including dividends.
- **From 52-week high: -18.4%** (92.2% above the low). Trading 18% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 44**. An RSI of 44 is neutral.
- **Beta (1 yr): 2.03** (volatility 61%). Beta of 2.03 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=IART · Page: https://foliofundamentals.com/stocks/iart

Not investment advice.